Get the Stockscreener App
6.88
5.52%
0.36
Fulcrum Therapeutics Inc stock is traded at $6.88, with a volume of 362.29K.
It is up +5.52% in the last 24 hours and down -2.41% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$6.52
Open:
$6.57
24h Volume:
362.29K
Relative Volume:
0.53
Market Cap:
$372.15M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-4.3544
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
+0.88%
1M Performance:
-2.41%
6M Performance:
+78.70%
1Y Performance:
-21.73%
1-Day Range:
$6.45
$6.915
1-Week Range:
$6.39
$7.09
52-Week Range:
$2.315
$9.90
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
6.88 | 359.17M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-12-24 | Downgrade | Stifel | Buy → Hold |
| Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-25-23 | Initiated | Goldman | Neutral |
| Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-22-23 | Upgrade | Stifel | Hold → Buy |
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
Full technical analysis of Fulcrum Therapeutics Inc. stockJuly 2025 Reactions & Technical Entry and Exit Alerts - Newser
Will Fulcrum Therapeutics Inc. benefit from macro trendsWeekly Trading Summary & Verified Momentum Stock Watchlist - Newser
Will earnings trigger a reversal in Fulcrum Therapeutics Inc.2025 Sector Review & Proven Capital Preservation Methods - Newser
Analyzing Fulcrum Therapeutics Inc. with risk reward ratio chartsJuly 2025 Earnings & Reliable Momentum Entry Alerts - Newser
Building trade automation scripts for Fulcrum Therapeutics Inc.Gold Moves & AI Enhanced Trading Alerts - Newser
Analysts Apply Wyckoff Model to Fulcrum Therapeutics Inc. Stock2025 Investor Takeaways & Reliable Breakout Stock Forecasts - kangso.co.kr
How high can Fulcrum Therapeutics Inc. stock goQuarterly Profit Summary & Daily Volume Surge Signals - Newser
Risk vs reward if holding onto Fulcrum Therapeutics Inc.2025 Volatility Report & Fast Exit and Entry Trade Guides - Newser
What indicators show strength in Fulcrum Therapeutics Inc.Weekly Profit Recap & Safe Entry Trade Reports - Newser
Real time pattern detection on Fulcrum Therapeutics Inc. stockJuly 2025 Catalysts & Reliable Price Action Trade Plans - Newser
Published on: 2025-08-19 17:11:19 - Newser
Is Fulcrum Therapeutics Inc. meeting your algorithmic filter criteriaWeekly Profit Analysis & Reliable Entry Point Trade Alerts - Newser
Applying big data sentiment scoring on Fulcrum Therapeutics Inc.Trade Risk Report & Free Expert Approved Momentum Trade Ideas - Newser
Will earnings trigger a reversal in Fulcrum Therapeutics IncSell Signal & Daily Volume Surge Trade Alerts - Newser
Will Fulcrum Therapeutics Inc. rebound enough to break evenPortfolio Growth Summary & Weekly Top Gainers Alerts - Newser
When is the best time to exit Fulcrum Therapeutics Inc.July 2025 Sector Moves & Stepwise Entry and Exit Trade Signals - Newser
Measuring Fulcrum Therapeutics Inc.’s beta against major indicesPortfolio Gains Report & Verified Stock Trade Ideas - Newser
Using Ichimoku Cloud for Fulcrum Therapeutics Inc. technicalsPortfolio Value Summary & Low Risk Entry Point Tips - Newser
Fulcrum defended at H.C. Wainwright after data for sickle cell disease drug - MSN
Comparing Fulcrum Therapeutics Inc. in custom built stock radarsMarket Movement Recap & Long Hold Capital Preservation Plans - Newser
Is Fulcrum Therapeutics Inc. a Top Dividend Stock to Watch in 2025Stock Surge & Free High Accuracy Swing Entry Alerts - Newser
Chart overlay techniques for tracking Fulcrum Therapeutics Inc.2025 Big Picture & Free Safe Capital Growth Stock Tips - Newser
Forecasting Fulcrum Therapeutics Inc. price range with options dataTreasury Yields & Community Verified Swing Trade Signals - Newser
Quant Models Detect Momentum Reversal in Fulcrum Therapeutics Inc.2025 Trading Volume Trends & Proven Capital Preservation Methods - sundaytimes.kr
What recovery options are there for Fulcrum Therapeutics Inc.Market Growth Summary & Real-Time Volume Trigger Notifications - Newser
Will Fulcrum Therapeutics Inc. Bounce From 52 Week LowTrade Signal Summary & Free Low Drawdown Momentum Trade Ideas - classian.co.kr
XTX Topco Ltd Takes Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World
What makes Fulcrum Therapeutics Inc. stock price move sharplyJuly 2025 Market Mood & Risk Managed Investment Strategies - Newser
Technical signs of recovery in Fulcrum Therapeutics Inc.2025 Trading Volume Trends & Real-Time Market Trend Scan - Newser
Key External Factors That Drive Fulcrum Therapeutics Inc. Stock Price MovementsFree Entry Alert Based on Volume Spikes - Newser
Does Fulcrum Therapeutics Inc. qualify in momentum factor screeningBollinger Band Squeeze and Expansion Analysis - Newser
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):